BMO Capital analyst Alex Arfaei maintained a Hold rating on Bristol Myers (NYSE: BMY) today and set a price target of $47. The company’s shares opened today at $53.94.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 5.4% and a 68.2% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and AstraZeneca.
Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $60.33.
See today’s analyst top recommended stocks >>
Based on Bristol Myers’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.19 billion and net profit of $1.49 billion. In comparison, last year the company earned revenue of $4.93 billion and had a net profit of $1.57 billion.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
